Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injection
NCT04419233 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2023-12-07
Summary
The primary objective of this study is to evaluate the safety of nusinersen sodium injection in the postmarketing setting in China.The secondary objectives are to collect data on the efficacy and the pharmacokinetics of nusinersen sodium injection in the post-marketing setting in China.
Conditions
- Muscular Atrophy, Spinal
Interventions
- DRUG
-
Nusinersen Sodium Injection
Administered as specified in the treatment arm.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Medical Director · Biogen
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-11-18
- Primary Completion
- 2023-11-21
- Completion
- 2023-11-21
Countries
- China
Study Locations
More Related Trials
-
An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)
NCT01494701 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)
NCT02292537 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)
NCT04729907 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Adults With SMA Treated With Nusinersen
NCT04591678 ·Status: COMPLETED
-
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy
NCT02193074 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).
NCT02462759 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
NCT02386553 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)
NCT04488133 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Nusinersen on Adults With Spinal Muscular Atrophy
NCT03878030 ·Status: COMPLETED
-
Pulmonary Function Test Changes and Respiratory Muscle Strength Trends in Spinal Muscular Atrophy Patients Receiving Nusinersen Treatments
NCT04050852 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies
NCT02594124 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study Evaluating the Safety and Efficacy of SKG0201 Injection in Patients With Spinal Muscular Atrophy Type 1
NCT06191354 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Ultrasound-assisted vs Landmark Based Intrathecal Administration of Nusinersen
NCT04674618 ·Status: COMPLETED ·Phase: NA
-
Responsiveness and Validation Study of MFM-20 in SMA Patients Treated With Nusinersen
NCT04644393 ·Status: UNKNOWN
-
A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)
NCT05067790 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Exploratory Study of NS-089/NCNP-02 in DMD
NCT04129294 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of the Functional Effects of Nusinersen in 5q-spinal Muscular Amyotrophy Adults (SMA Type 2 or 3 Forms)
NCT04576494 ·Status: COMPLETED ·Phase: NA
-
Exploratory Study of NS-065/NCNP-01 in DMD
NCT02081625 ·Status: COMPLETED ·Phase: PHASE1
-
Metabolomics of Children With SMA
NCT04587492 ·Status: COMPLETED
-
An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy
NCT06288230 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Ultrasound-assisted or Landmark-based Intrathecal Administration of Nusinersen in Adult Patients With Spinal Muscular Atrophy (The EchoSpin Study)
NCT05644899 ·Status: COMPLETED
-
A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS
NCT07169175 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1
NCT05614531 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
A Trial of Hydroxyurea in Spinal Muscular Atrophy
NCT00485511 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
NCT05337553 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3